Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
Cyclic peptide conjugates and methods of use
US11078235B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11078235-B2 |
| Application number | US-201816025382-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 2, 2018 |
| Priority date | Sep 27, 2013 |
| Publication date | Aug 3, 2021 |
| Grant date | Aug 3, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
First claim
Opening claim text (preview).
What is claimed is: 1. A carrying agent:cyclic compound adduct having the structure: wherein X comprises a carrying agent and z is 1 to 20. 2. The carrying agent:cyclic compound adduct of claim 1 , wherein said carrying agent comprises an amino acid, oligo(amino acid), poly(amino acid) or protein. 3. A composition comprising a cyclic compound of claim 2 ; and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
- C07K7/08Primary
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} · CPC title
Molecules with a "CD"-designation not provided for elsewhere · CPC title
Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11078235B2 cover?
- The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant …
- Who is the assignee on this patent?
- H Lee Moffitt Cancer Ct & Res, Univ South Florida, Scripps Research Inst, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K7/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).